Abstract
Hawaii has one of the highest incidences of Campylobacteriosis in the United States, but there remains little published data on circulating strains or antimicrobial resistance. We characterized 110 clinical Campylobacter isolates (106 C. jejuni, 4 C. coli) processed at Tripler Army Medical Center in Honolulu, HI from 2012–2016. Twenty-five percent of C. jejuni isolates exhibited fluoroquinolone (FQ) resistance, compared with 16% for tetracycline (TET), and 0% for macrolides. Two of the four C. coli isolates were resistant to FQ, TET, and macrolides. C. jejuni isolates further underwent multilocus sequence typing, pulsed-field gel electrophoresis, and molecular capsular typing. Nineteen capsule types were observed, with two capsule types (HS2 and HS9) being associated with FQ resistance (p < 0.001 and p = 0.006, respectively). HS2 FQ-resistant isolates associated with clonal complex 21, possibly indicating clonal spread in FQ resistance. Macrolides should be considered for treatment of suspect cases due to lack of observed resistance.
Highlights
Campylobacteriosis, usually caused by Campylobacter jejuni, is the most common cause of bacterial gastroenteritis in the United States, responsible for 1.3 million cases annually
Pike et al published a systematic review on the epidemiology of C. jejuni capsular types, noting the vast majority of information on circulating strains came from Europe (87%), with the US, Asia, and Oceania making up 12%, highlighting the need for more global serotypes to guide multivalent vaccine development[22]
Species was identified as C. jejuni in 106 isolates and C. coli in 4 isolates
Summary
Campylobacteriosis, usually caused by Campylobacter jejuni, is the most common cause of bacterial gastroenteritis in the United States, responsible for 1.3 million cases annually. It is usually contracted through consumption of contaminated food products – poultry, dairy, pork, or contaminated water[1]. Pike et al published a systematic review on the epidemiology of C. jejuni capsular types, noting the vast majority of information on circulating strains came from Europe (87%), with the US, Asia, and Oceania making up 12%, highlighting the need for more global serotypes to guide multivalent vaccine development[22]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.